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Abstract 
Background: The efficacy/safety of device-supported versus routine titration with 
Gla-300 in type 2 diabetes (T2DM) was evaluated. 
Method: AUTOMATIX was a 16-week, randomized, open-label, parallel-group, 
multicenter, non-inferiority trial in insulin-treated or insulin-naïve people with 
T2DM. The fasting self-monitored plasma glucose (FSMPG) target was 90–130 mg/dL 
(5.0–7.2 mmol/L). Primary endpoint: proportion of participants achieving target 
FSMPG at week 16 without severe hypoglycemia. Secondary endpoints included:  
proportion reaching FSMPG target without confirmed (≤70 mg/dL [≤3.9 mmol/L]) or 
severe hypoglycemia; time to first achieve FSMPG target; mean FSMPG and HbA1c 
change (baseline to week 16). Safety endpoints included hypoglycemia and adverse 
events. Patient-reported outcomes (PROs) were also assessed. 
Results: Participants were randomized to device-supported (n=75) or routine 
titration (n=76); 17 participants in the device-supported group discontinued device 
use. Noninferiority was achieved for the primary endpoint (device-supported: 
45.9%, routine: 36.8%; weighted difference: 9.04 [95%CI: -6.75, 24.83]), but not 
superiority (p=0.262). The proportion reaching FSMPG target range without 
confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemia was 34.3% versus 
14.5%, respectively. The time at which 50% of the participants achieved the FSMPG 
target was less in the device-supported than routine titration arm (10- vs 13-weeks). 
Least squares mean HbA1c reduction, safety profiles, and PROs were similar in both 
arms. Mean ‘ease of use’ score for the device, assessed by healthcare professionals 
and participants on a scale of 1–7, was ≥6. 
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Conclusions: Device-supported self-titration had a good safety/efficacy profile, and 
was non-inferior to routine titration and well accepted by diabetes specialists and 
patients. 
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Introduction 
Type 2 diabetes (T2DM) is usually treated initially with oral antihyperglycemic drugs 
(OADs), but as the disease progresses many individuals need insulin to maintain 
glycemic control.1 Despite recommendations that basal insulin (BI) therapy is 
initiated in those unable to achieve or maintain the recommended HbA1c target 
(<7.0 %, 53 mmol/mol) after 3 months at maximum tolerated doses of OADs,2 
suboptimal glycemic control with OADs may continue for up to 7 years before insulin 
initiation.3 Even after BI is initiated, approximately 70% of individuals are unable to 
titrate the dose appropriately and fail to reach recommended glycemic targets;4 if 
targets are initially achieved, subsequently over 50% of these individuals fail to 
maintain long-term glycemic control.5 The failure to achieve or maintain glycemic 
control can be attributed to a significant delay in the initiation and dose optimization 
of BI, often termed as ‘clinical inertia’, and defined as the ‘failure of healthcare 
providers to initiate or intensify therapy when indicated’.6 Addressing issues that 
contribute to clinical inertia (e.g. fear of undesirable side effects, lack of self-
confidence in adhering to complex regimens, lack of trust in the efficacy of insulin 
etc.7), and achieving optimal BI-dose titration is key to ensuring individuals achieve 
and maintain optimal-glucose control.3 
 
Healthcare providers (HCPs) should strike a balance between the need for tight 
glycemic control early in T2DM, with its associated benefits of reduced risk of 
macrovascular and microvascular complications, myocardial infractions and death,8, 9 
with the risk of hypoglycemia.10 In the real-world setting BI dose is often titrated at 
the treating physician’s discretion during routine-clinic visits. While such visits 
provide support for individuals and allow HCPs to provide consistent advice and 
Page 7 of 42 
 
simple treatment algorithms, they may be infrequent (e.g. at 3-monthly intervals or 
longer), and delay insulin intensification. Empowering and supporting people with 
T2DM to self-titrate their BI dose could enable more individuals to achieve optimal 
glycemic control with fewer delays.11 For example, better glycemic control with BI 
has been observed when dose titration was self-managed every 3 days rather than 
physician-led weekly-dose titration.12 It has also been observed that when 
individuals with T2DM are involved in treatment decision-making, their 
understanding of diabetes care increases and positively impacts upon their self-
management.13 Device-supported self-titration may empower individuals with T2DM 
by allowing them to make informed treatment decisions without having to rely as 
much on HCPs and may also improve understanding of dose optimization to better 
self-manage their condition. 
 
MyStar DoseCoach® is an integrated titration device/blood glucose meter designed 
to assist people with T2DM to self-titrate insulin glargine by providing automated 
dosing suggestions. The AUTOMATIX study aimed to compare the efficacy and safety 
of a device-supported treat-to target regimen versus diabetes knowledgeable 
investigator-recommended routine titration with Gla-300 in people with T2DM. 
  
Methods 
Study design and participants 
AUTOMATIX (NCT02585674) was an open-label, randomized, controlled, parallel-
group, multicenter, phase 3 study in people with T2DM conducted at 19 study 
centers (Supplementary Figure 1). The study was performed in accordance with the 
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Good Clinical Practice and the Declaration of Helsinki. All participants provided 
written informed consent.  
 
Participants were aged ≥18 years, with T2DM for ≥1-year, either insulin-naïve or 
previously treated with BI, with HbA1c between 7.5–11.0 % (58–97 mmol/mol 
inclusive) and fasting self-monitored plasma glucose (FSMPG) >130 mg/dL (7.2 
mmol/L). Key exclusion criteria (Supplementary Materials) included diabetes other 
than T2DM, device-supported titration not being appropriate or use of device 
otherwise contraindicated (in the opinion of the investigator), and the use of 
mealtime insulin for more than 10 days in the last 3 months before screening. 
 
Randomization and treatment 
All participants were given a titration device/blood glucose meter (MyStar 
DoseCoach®, Agamatrix Inc., Salem NH, US), and self-administered Gla-300 
subcutaneously once-daily. Participants were randomized 1:1 to either device-
recommended titration (the titration feature was activated by investigator at 
randomization visit 3) or routine titration (titration feature of the device turned off) 
as recommended by the investigator, who were diabetes specialists, stratified by 
previous use of insulin (insulin naïve vs insulin treated). For insulin-naïve 
participants, the starting daily dose of Gla-300 was 0.2 U/kg body weight. 
Participants on previous BI therapy were switched to the same daily dose if they had 
been receiving once-daily Gla-100/neutral protamine Hagedorn (NPH) insulin/insulin 
detemir and to 80% of the previous daily dose if they had been receiving more than 
once-daily NPH insulin/insulin detemir.  
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Dosing recommendations (Supplementary Table 1) for participants randomized to 
the device-supported titration were provided by the device titration meter after a 
minimum of 3 consecutive days of FSMPG and insulin dose data, based on a FSMPG 
target range of 90–130 mg/dL (5.0–7.2 mmol/L). Participants who discontinued 
device-supported titration recommendations, for whatever reason, continued until 
the study end and followed the titration recommendations provided by the 
investigator from the time of discontinuation. 
 
Outcomes 
The primary efficacy endpoint was the percentage of participants reaching a FSMPG 
target of 90–130 mg/dL (5.0–7.2 mmol/L) following 16 weeks of treatment without 
severe hypoglycemia. Reaching the FSMPG target range required the mean of the 
last five FSMPG readings recorded in the previous 2 weeks to be within the target 
range before the end of the 16-week on-treatment period.  
 
Secondary efficacy endpoints included percentages of participants reaching target 
FSMPG range (90–130 [5.0–7.2 mmol/L]) following 16 weeks of treatment without 
confirmed (≤70 mg/dL [3.9 mmol/L] or <54 mg/dL [3.0 mmol/L]) or severe 
hypoglycemia events, time to first reach FSMPG target, change in mean FSMPG, 
change in HbA1c and mean central laboratory measured fasting plasma glucose (FPG) 
from baseline to week 16, and percentage of participants with FPG in the target 
range of 90–130 mg/dL (5.0–7.2 mmol/L) without severe hypoglycemia at the week 
16 time point.  
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Safety endpoints included hypoglycemia, categorized based upon American Diabetes 
Association (ADA) definitions (Supplementary Methods),2 adverse events (AEs), and 
meter- and pen-related events as reported by the participant or noted by the 
investigator. Hypoglycemia endpoints included the percentage of participants 
reporting ≥1 events. 
Patient reported outcomes (PROs) were assessed using PRO/questionnaires 
including the diabetes treatment satisfaction questionnaire (DTSQs),14 the 
hypoglycemia fear survey (HFS-II),15 the diabetes distress scale,16 the glucose 
monitoring satisfaction survey (GMS)17, with emotional well-being analyzed using 
the WHO-5 well-being index.18 Ease of use of the device was assessed in HCPs and 
participants during week 16 using questionnaires consisting of a series of questions 
to which responses were rated from 1 (extremely difficult) to 7 (extremely easy).  
 
Statistical analysis 
A sample size of 148 participants (74 per titration arm) was estimated to 
demonstrate non-inferiority of the device-supported arm with a 0.15 margin for the 
difference versus routine titration, 80% power and 2.5% one sided alpha; assuming 
the proportion reaching the FSMPG target range without severe hypoglycemia 
during the on-treatment period was 0.42 (routine-titration) and 0.50 (device-
supported titration). All efficacy endpoints were analyzed or summarized for the 16-
week on-treatment period using the modified intent-to-treat (mITT) population 
(Supplementary Materials), unless otherwise specified. 
 
The primary endpoint was analyzed using a multiple imputation approach 
(Supplementary Materials), using effect estimators of titration regimen, weighted by 
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the randomization stratum of previous use of insulin. A stepwise closed-testing 
approach was used to first assess non-inferiority followed by superiority of device-
supported versus routine titration. Non-inferiority required the lower bound of the 
two-sided 95% CI for the difference in percentage of participants between titration 
arms to be greater than the predefined non-inferiority margin of -15%. If the non-
inferiority was demonstrated, superiority required the lower bound of the two-sided 
95% CI for the weighted difference in the % of participants between titration arms to 
be >0. 
 
A similar multiple imputation approach was used to assess the secondary efficacy 
endpoints related to percentage of participants reaching FSMPG target range 
without a hypoglycemic event. Change in mean FSMPG from baseline to the end of 
the 16-week on-treatment period was analyzed using a mixed model for repeated 
measures (MMRM) approach (Supplementary Materials). Time to first FSMPG target 
range of 90–130 mg/dL (5.0–7.2 mmol/L) was defined by the first 2-week period in 
which the mean FSMPG of the last 5 values was within target (Supplementary 
Materials). Change in HbA1c from baseline to week 16 was analyzed using an analysis 
of covariance (ANCOVA) model (Supplementary Materials). Change in mean FPG 
from baseline to week 16 was analyzed using a MMRM approach, while the pre-
specified FPG target was analyzed using a Cochran Mantel Haenszel (CMH) method 
(Supplementary Materials). Safety analyses were descriptive and based on the safety 
population (Supplementary Materials). 
 
The change in score from baseline to week 16 for each PRO/questionnaire was 
analyzed in the mITT population using ANCOVA. The percentage of PROs responders 
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based on the minimum clinically-important difference (MCID) was analyzed using a 
CMH method (Supplementary Materials). 
 
Results 
Study population 
In total, 151 participants with T2DM were enrolled from 19 centers (device-
supported titration, n=75; routine titration, n=76) (Supplementary Figure 2). All 
participants were exposed to Gla-300 and included in the safety and mITT 
populations. Five participants (6.7%) in the device-supported titration arm did not 
complete the study period and permanently discontinued Gla-300 treatment 
(Supplementary Figure 2). Overall, 17/75 (23%) of the participants randomized to 
the device-supported arm discontinued use of device, 9 (12%) due to 
misunderstanding the device titration function and 8 (11%) due to other reasons 
including withdrawal of consent (Supplementary Figure 2). Baseline characteristics 
(Table 1) were generally well balanced across the two arms with a slightly higher 
proportion of females in the device-supported titration versus routine titration arm 
(36.0% vs 26.3%). All enrolled participants were Caucasians.  
 
Efficacy outcomes 
The percentage of participants who achieved the primary endpoint, FSMPG in the 
target range of 90–130 mg/dL after 16-weeks of treatment without severe 
hypoglycemia, was 45.9% in the device-supported titration arm compared with 
36.8% in the routine-titration arm (weighted difference: 9.04 [95% CI: −6.75 to 
24.83], Figure 1). Non-inferiority of the device-supported versus the routine-titration 
arm was demonstrated as the lower bound of the 95% CI for the weighted 
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difference in percentage of patients between arms (9.04; 95 % CI [-6.748 to 24.829]) 
was greater than the predefined non-inferiority margin of -15%. Superiority of 
device-supported versus routine-titration was not statistically shown (p=0.262). 
 
The percentage of participants who reached the FSMPG target range without 
confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemia was higher in the 
device-supported than the routine titration group (34.3% vs 14.5%; [weighted 
difference: 19.75 (95% CI: 6.28 to 33.21)], Figure 1). A comparable proportion of 
participants in the device-supported and routine-titration arm (40.0% vs 34.2%) 
reached the FSMPG target range without confirmed (<54 mg/dL [<3.0 mmol/L]) or 
severe hypoglycemia.  
 
The Kaplan-Meier cumulative incidence curves of participants reaching the FSMPG 
target of 90–130 mg/dL showed an overall shorter time to reach the FSMPG target 
in the device-supported titration arm than the routine arm, but this trend was 
driven by participants who did not reach the target within the first 8 weeks 
(p=0.171). The time at which 50% of the participants achieved the FSMPG target was 
less in the device-supported than in the routine-titration arm (10 weeks [95% CI: 8–
10] vs 13-weeks [95% CI: 6–16], respectively). Mean FSMPG (mean of the last 5 
readings recorded over the last 2 weeks) reduced from baseline to the week 16 
time-point in both titration arms, (least squares [LS] mean change −41.7 mg/dL vs –
43.3 mg/dL; Table 2 and Figure 2). 
 
The LS mean reduction in HbA1c from baseline to week 16 was similar in the device-
supported (−1.12 %) and the routine-titration (−1.07 %) arms (Table 2). 
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For laboratory measured FPG, both titration groups showed reductions from 
baseline to week 16, although the reductions were slightly lower in the device-
supported than the routine-titration arm (−44.05 mg/dL vs −49.46 mg/dL). The 
percentage of participants with laboratory measured FPG in the target range of 90–
130 mg/dL (5.0–7.2 mmol/L) without severe hypoglycemia at week 16 was also 
higher in the routine-titration arm (29.3% vs 43.4%; Table 2), which may be due to a 
higher mean (standard deviation [SD]) FPG value at baseline in the device-
supported arm (192.30 [39.83] mg/dL vs 186.78 [47.15] mg/dL).  
 
Basal insulin dose 
During the study, BI dose rose steadily in both treatment arms and the change in 
average BI dose from baseline to week 16 was 0.213 (SD: 0.185) U/kg and 0.157 (SD: 
0.153) U/kg in the device-supported and routine-titration arms, respectively. 
 
Safety 
The percentage of participants with at least one hypoglycemic event in any category 
including nocturnal (00:00–05:59 h) hypoglycemia during the on-treatment period 
was generally comparable between both the titration arms (Figure 3). A slightly 
higher proportion of participants in the routine-titration arm reported at least one 
asymptomatic hypoglycemic event (27.6%), and at least one confirmed (≤70 mg/dL 
[3.9 mmol/L]) or severe hypoglycemic event (35.5%) during the on-treatment period 
compared with that in the device-supported arm (20.0% and 29.3%, respectively). 
One case of severe hypoglycemia was reported in the routine-titration arm. 
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The safety profile was comparable between the titration arms (Supplementary Table 
2). For participants in the device-supported arm, the proportion of treatment-
emergent adverse events (TEAEs) during on-treatment period and device-support 
period were similar. The proportion of TEAEs was slightly higher in the device-
supported versus routine titration arm (45.3% vs 38.2%). However, the proportion of 
serious TEAEs was slightly lower in the device-supported versus routine-titration 
arm (2.7% vs 3.9%). No TEAE resulted in treatment discontinuation or death. 
 
The percentage of participants with at least one meter-related event (MRE) was 
higher in the device-supported arm compared with the routine-titration arm (70.7% 
vs 9.2%) and mainly related to the functionality of the device (not activated in the 
routine-titration arm as per protocol) (Supplementary Table 2). The percentage of 
participants with at least one pen-related event(s) was low and comparable 
between the device-supported and routine-titration arms (4.0% vs 3.9%). 
 
Patient reported outcomes 
Overall, there were no major differences in PROs between the device-supported and 
routine-titration arms (Supplementary Table 3). For DTSQ total treatment 
satisfaction score, the LS mean change from baseline to week 16 was 4.46 using 
routine-titration versus 2.90 using device-supported titration (Supplementary Table 
3). The LS mean change in HFS-II scores were similar for both titration arms at week 
16 (Supplementary Table 3). There was little change in Diabetes Distress Scale scores 
from baseline to week 16 for both titration arms with no clinically-relevant 
differences between arms in the proportion of participants reaching the MCID 
(Supplementary Table 3). Improvements in GMS from baseline to week 16 was seen 
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in both titration arms (Supplementary Table 3). LS mean change in WHO-5 well-
being index scores from baseline to week 16 were −0.03 and 6.20 for device-
supported group and routine group, respectively (Supplementary Table 3). 
 
Participants were asked to rate how easy or difficult it was to use the device on a 
scale of 1–7 with 1=very difficult and 7=very easy. The mean scores for how easy it 
was “to decide what insulin dose to take”, “to do the dose calculations correctly” 
and “to adjust their insulin dose” were 6.11, 6.07 and 6.24 indicating that individuals 
found the device easy to use. 
 
Discussion 
AUTOMATIX indicates that device-supported titration with Gla-300 was statistically 
non-inferior to diabetes knowledgeable, investigator-led routine titration in 
achieving the FSMPG target of 90–130 mg/dL (5.0–7.2 mmol/L) without 
experiencing severe hypoglycemia. Most people with T2DM and HCPs found the 
device easy to use. As discussed below, however, the higher number of MRE, and 
the finding that 23% of individuals in the device-supported arm discontinued using 
the device indicates that further improvements to the training/support provided to 
users, or changes to improve device ease of use, may be required. 
 
Previously it has been suggested that based on their knowledge, expertise or 
interest in the use of technology, some individuals may need additional guidance 
and support as they may not like technical language while others may need more 
extensive details.19 Participants had a mean age >60 years, with 44% being aged 65 
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years or over, a group at higher risk of cognitive impairment compared with 
younger-age groups,2 which may impact on their ability to correctly understand 
instructions and use the device. In total, 17 participants (23%, mean age: 60.6 years; 
range: 42–74 years) discontinued device-supported titration, of whom 9 (12%) 
discontinued due to a misunderstanding of the device function. This limited number 
of participants does not allow an assessment of whether older age and cognitive 
ability may have been a contributing factor. However, as approximately 70% of 
individuals in the device-supported group experienced MREs, which included user 
error in operating the device (e.g. not tagging the FSMPG reading or the incorrect 
inputting of the insulin dose used), misunderstanding device instructions, and device 
malfunctions, it appears that increasing participant age is unlikely to underpin these 
errors. There were also some minor differences in patient-reported treatment 
satisfaction and well-being that favored routine titration that did not reflect any 
disparities in HCP contact between the groups. Overall, these findings suggest that 
discontinuations could be a potential challenge in managing compliance with device 
use in a minority of individuals, and that this device may not be suitable for all 
individuals with T2DM who wish to use device-supported titration. These outcomes 
highlight the need for careful selection of patients in whom use of the device is 
most appropriate and the need to provide appropriate training in its use. To 
facilitate this, based on AUTOMATIX, the device user interface has subsequently 
been optimized and the training materials reworked, for example, to simplify tagging 
of the FSMPG reading (Supplementary Table 4). 
 
Technological advances to aid insulin titration have demonstrated improved 
outcomes and safety in both type 1 diabetes (T1DM) and T2DM in several studies. 20 
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21, 22 23 24 25 The INNOVATE study examined titration with insulin glargine 100 U/mL 
(Gla-100) using the long-acting insulin glargine titration web tool (LTHome) in 
T2DM,26 using the same rules and engine-based algorithm for titration as that for 
MyStar DoseCoach®. Of note, a similar percentage of participants reached FPG 
targets without experiencing hypoglycemia with LTHome as with device-supported 
titration observed in AUTOMATIX (47% vs 45.9%, respectively). There were similar 
HbA1c reductions in the LTHome versus the enhanced usual therapy (EUT) arm, but 
with the EUT arm receiving more HCP resources. While cost-effectiveness data were 
not collected in AUTOMATIX, the potential for device-supported titration to cut 
healthcare costs by enabling people with T2DM to achieve glycemic targets while 
reducing the involvement of physicians and other ancillary healthcare services is of 
interest. 
 
In AUTOMATIX, outcomes reported for the routine-titration arm were probably 
better than that observed in the real world. Participants in AUTOMATIX were 
instructed by investigators (all diabetes specialists with extensive experience 
working with T2DM) on the recommended method for titration of Gla-300 at each 
scheduled visit, whereas in real life, routine BI titration in many people with T2DM is 
not as well managed and follow-up visits are generally less frequent than the 
clinical-trial setting. Therefore, the numerical difference seen in AUTOMATIX might 
be predictive of more clinically-meaningful differences in real-life clinical practice, 
and it is possible that differences in outcomes between device-titration and routine-
titration could be better demonstrated using a real-world study. While the 
performance of device-supported titration is less likely to be affected by infrequent 
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clinic visits in clinical practice, outcomes in the routine-titration group may be 
poorer. 
 
The limitations of AUTOMATIX are those inherently associated with the use of 
devices and device-titration. The open-label trial design and the use of block 
randomization instead of cluster randomization could have been a potential source 
of bias. Dosing recommendations were not standardized for the routine-titration 
arm, and were at the discretion of each investigator, which may have contributed to 
dosing variability and influenced target achievement; although, this may also be 
considered a strength of the study as it ensures that the control is more 
representative of real-life practice despite the caveats mentioned above. Several 
variables may have influenced target achievement in the routine-titration arm that 
were not able to be controlled (e.g. participant behavior, potential investigator bias, 
and participant education on how to titrate). Lastly, the short trial duration may 
have been insufficient to allow observations on long-term challenges in adherence 
to titration device, and longer term, real-world studies would be of interest. 
 
Conclusions 
Device-supported titration with Gla-300 demonstrated a good safety profile and was 
non-inferior to routine titration (led by diabetes specialists), with a trend towards 
shorter times being needed to reach FSMPG target. While further work to support 
people with T2DM in terms of making the device easier to use and providing suitable 
training materials is required, this study provides additional support for device-
supported insulin titration. By helping individuals to make timely and sensible dosing 
choices, devices such as MyStar DoseCoach® and other innovative technologies may 
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help to address the clinical inertia in optimizing insulin dosing.
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Tables 
Table 1. Baseline demographics and patient characteristics (randomized 
population) 
 Device-supported 
titration 
n=75 
Routine 
titration 
n=76 
All 
N=151 
Age, years, mean (SD) 61.2 (9.5) 62.9 (9.4) 62.1 (9.5) 
Age group, years, n (%) 
<65  
65–75 
≥75 
43 (57.3) 
29 (38.7) 
3 (4.0) 
42 (55.3) 
24 (31.6) 
10 (13.2) 
85 (56.3) 
53 (35.1) 
13 (8.6) 
Sex, n (%) 
Male 
Female 
48 (64.0) 
27 (36.0) 
56 (73.7) 
20 (26.3) 
104 (68.9) 
47 (31.1) 
Race, Caucasian, n (%) 75 (100) 76 (100) 151 (100) 
Body Weight, kg, mean (SD) 96.9 (24.0) 100.0 (23.8) 98.5 (23.8) 
BMI, kg/m2, mean (SD) 33.2 (6.9) 33.3 (7.0) 33.2 (6.9) 
BMI categories, kg/m2, n (%) 
<25 
25–30 
30–40 
≥40 
 
5 (6.7) 
24 (32.0) 
35 (46.7) 
11 (14.7) 
 
5 (6.6) 
20 (26.3) 
37 (48.7) 
14 (18.4) 
 
10 (6.6) 
44 (29.1) 
72 (47.7) 
25 (16.6) 
Estimated GFR, L/min/1.73m2, 
mean (SD) 
82.02 (27.60) 84.04 (24.02) 83.04 (25.80) 
Estimated GFR categories, n (%) 
≥90 
60–90 
30–60 
 
22 (29.3) 
40 (53.3) 
13 (17.3) 
 
33 (43.4) 
30 (39.5) 
13 (17.1) 
 
55 (36.4) 
70 (46.4) 
26 (17.2) 
Randomization stratuma 
(previous insulin use) 
Insulin-naïve 
Insulin-pretreated 
 
 
30 (40.0) 
45 (60.0) 
 
 
30 (39.5) 
46 (60.5) 
 
 
60 (39.7) 
91 (60.3) 
aDue to stratification errors, 4 insulin pre-treated participants were randomized as insulin-naïve and 1 
insulin-naïve participant was randomized as insulin pre-treated.  
BMI, body mass index; GFR, glomerular filtration rate; SD, standard deviation 
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Table 2. Secondary efficacy outcomes during the 16 week on-treatment period (modified intent-to-treat population) 
 Device-supported 
titration 
n=75 
Routine titration  
n=76 
LS Mean difference 
(SE) vs. routine 
titration, 95% CI 
Change in mean FSMPG from baseline to 
week 16 time-point, LS mean (SE) mg/dL 
 
−41.70 (3.32) −43.26 (3.18) 1.56 (4.60), −7.55 to 
10.66 
Change in HbA1c from baseline to week 16, 
LS mean (SE) % 
  
−1.12 (0.09) −1.07 (0.08) −0.05 (0.12), −0.29 
to 0.19 
Change in FPG from baseline to week 16, 
LS mean (SE) mg/dL 
 
−44.05 (4.26) −49.46 (4.08) 5.40 (5.91), −6.28 to 
17.09 
 
 Device-supported 
titration 
n=75 
Routine titration  
n=76 
RR (95% CI) vs. 
routine titrationa 
Laboratory measured FPG at target (90–
130 mg/dL [5.0–7.2 mmol/L]) at week 16 
without severe hypoglycemia, n (%) 
22 (29.3) 33 (43.4) 0.67 (0.438 to 
1.039) 
aBased on RR stratified by randomization stratum of previous use of insulin (insulin naïve, insulin pre-treated), using a CMH (Cochran Mantel Haenszel) methodology 
CI, confidence interval; FPG, fasting plasma glucose; LS, least squares; RR, relative risk, SD, standard deviation; SE, standard error; FSMPG, fasting self-monitored plasma 
glucose 
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Figures 
Figure 1. Estimated percentage of participants achieving target FSMPG without 
hypoglycemia during the 16-week on-treatment period (modified intent-to-treat 
population) 
 
aEstimated proportion of participants was obtained using a multiple imputation 
method was to address missing values in the mITT population 
bEstimated weighted difference of proportions obtained by combining the difference 
in percentage, weighted by the randomization stratum of previous use of insulin 
(insulin naive, insulin pre-treated), between titration groups of all different imputed 
data sets 
CI, confidence interval; FSMPG, fasting self-monitored plasma glucose 
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Figure 2. Mean change in FSMPG over the 16-week on treatment period (modified 
intent-to-treat population) 
 
FSMPG, fasting self-monitored plasma glucose 
 
Supplementary materials 
31 
 
Figure 3. Incidence (%) of participants experiencing ≥1 hypoglycemic event during 
the on-treatment period (safety population) 
 
 
 
 
 
 
 
 
Supplementary materials 
32 
 
Supplementary methods 
Exclusion Criteria 
➢ Age <18 years 
➢ Diabetes other than type 2 diabetes mellitus 
➢ MyStar DoseCoach™ device was not appropriate for the patient or use of device 
was otherwise contraindicated (in the opinion of the investigator) 
➢ Conditions/situations that were contraindications or off-label use according to 
Summary of 
Product Characteristics (SmPCs) of oral antihyperglycemic drugs (OADs) and/or 
glucagon-like peptide-1 (GLP-1) receptor agonists when applicable (prescribed), 
or insulin glargine and as defined in the national product label 
➢ Patients not on stable doses of glucose lowering therapy including OADs, GLP-1 
receptor agonists, or basal insulin therapy, for the 3 months prior to screening 
(stable basal insulin therapy defined as maximum change in insulin dose of +/- 
20%) 
➢ Patients using mealtime insulin (short acting analogue, human regular insulin, or 
premix insulin) for more than 10 days in the last 3 months before screening visit 
➢ Patients with hypoglycemia unawareness 
➢ Patients with severe hypoglycemia in the past 90 days 
➢ Hospitalization in the past 30 days 
➢ Use of systemic glucocorticoids (excluding topical application or inhaled forms) 
for one week or more within 90 days prior to screening 
➢ Unable to meet specific protocol requirements (e.g., inability to perform blood 
glucose measurements, manage their own insulin glargine administration, or 
deemed unlikely to safely manage titration based on guidance by their physician, 
etc.), because of a medical condition or because the patient was under legal 
guardianship 
➢ Patients with cognitive disorders, dementia, or any neurologic disorder that 
would affect a patient's ability to participate in the study, including the inability 
to understand study requirements or to give complete information about adverse 
symptoms 
➢ Conditions/situations such as: 
• Patients with conditions/concomitant diseases precluding their safe 
participation in this study (e.g., active malignant tumor, major systemic 
diseases, presence of clinically significant diabetic retinopathy or presence of 
macular edema likely to require treatment within the study period, etc.) 
• Patients unable to fully understand study documents and to complete them. 
Patients who have a caregiver together with whom they can fulfill all study 
requirements are eligible 
• Patient is the Investigator or any Sub-Investigator, research assistant, 
pharmacist, study coordinator, other staff or relative thereof directly involved 
in the conduct of the protocol 
➢ Within the last 3 months prior to screening: history of myocardial infarction, 
unstable angina, acute coronary syndrome, revascularization procedure or stroke 
requiring hospitalization 
➢ Severe or uncontrolled Congestive Heart Failure (New York Heart Association 
[NYHA] functional classification III and IV); or inadequately controlled 
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hypertension at the time of screening with a resting systolic or diastolic blood 
pressure >180 mmHg or >95 mmHg, respectively 
➢ Pregnant or breast-feeding women or women who intend to become pregnant 
during the study period as glycemic control may be unstable and insulin doses 
may be variable during this period 
➢ Women of childbearing potential (premenopausal, not surgically sterile for at 
least 3 months prior to the time of screening) must use an effective contraceptive 
method throughout the study. Effective methods of contraception include barrier 
methods (in conjunction with spermicide), hormonal contraception, or use of an 
intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) 
 
Hypoglycemia categories 
Hypoglycemia endpoints included the percentage of participants reporting ≥1 event. 
Events were categorized based on American Diabetes Association (ADA) definitions: 
severe symptomatic hypoglycemia was defined as an event requiring third party 
assistance by another person to actively administer carbohydrate, glucagon, or other 
resuscitative actions; documented symptomatic hypoglycemia was defined as events 
during which typical symptoms of hypoglycemia were accompanied by a measured 
plasma glucose concentration of ≤70 mg/dL (≤3.9 mmol/L) or <54 mg/dL (<3.0 
mmol/L); asymptomatic hypoglycemia included events that were not accompanied 
by typical symptoms of hypoglycemia but with a measured plasma glucose 
concentration ≤70 mg/dL (≤3.9 mmol/L) or <54 mg/dL (<3.0 mmol/L); confirmed or 
severe hypoglycemia included events with a plasma glucose ≤70 mg/dL (≤3.9 
mmol/L) or <54 mg/dL (<3.0 mmol/L) or categorized as severe. 
 
Statistical analysis 
A total of 151 patients were randomized: 75 to the device-supported titration arm 
and 76 to the routine titration arm. The safety and modified intent-to-treat (mITT) 
populations included all 151 participants.  
 
The on-treatment period for efficacy endpoints was defined as the time from the 
first injection of investigational medicinal product (IMP) until 7 days for HbA1c, 2 
days for hypoglycemia, or 1 day for FPG and FSMPG, after the last injection of IMP. 
For endpoints related to mean FSMPG (except time to first mean FSMPG), only 
assessments recorded during the on-treatment period and within 112 days (16 
weeks) after the first injection of IMP were considered in the analyzes. The on-
treatment period for safety endpoints was defined as the time from the first 
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injection of IMP until 2 days after the last injection of IMP. The device-support 
period was defined as the time from the date of device-supported activation or from 
the 1st IMP dose, whichever was later for the participant, up to 2 days after the date 
of the end use of the device functionality or 2 days after the last injection of the 
IMP, whichever was earlier for the participant. 
 
The primary efficacy population was the mITT population, which included all 
randomized participants who were treated with Gla-300, analyzed according to the 
titration regimen group allocated by randomization. The safety population was 
defined as all randomized participants who received at least one dose of Gla-300, 
regardless of the amount of treatment administered and analyzed according to the 
titration regimen group actually followed. 
 
The primary endpoint was analyzed using a multiple imputation approach for 
handling missing mean FSMPG continuous values at any time point, and missing 
status regarding severe hypoglycemic events during the 16-week on-treatment 
period.  
 
Change in FSMPG from baseline to the end of the 16-week on-treatment period was 
analyzed using an mixed model for repeated measures (MMRM) approach on post-
baseline data available during the 16-week on-treatment period; the model included 
fixed categorical effects of regimen group, 2-week periods, regimen-by-2-week 
period interaction, randomization stratum of previous use of insulin (insulin-naïve vs 
non-insulin-naïve) as well as the continuous fixed covariates of baseline FSMPG 
value and baseline FSMPG value-by-2-week period interaction. 
 
Time to first FSMPG target range of 90–130 mg/dL (5.0–7.2 mmol/L) was defined by 
the first 2-week period in which the mean FSMPG of the last five values was in the 
target range and compared between the two titration regimen groups using the log-
rank-test procedure stratified by randomization stratum of previous use of insulin. 
The cumulative incidence curve of patients reaching FSMPG target range was 
estimated using Kaplan-Meier method. Change in HbA1c from baseline to week 16 
was examined using an analysis of covariance (ANCOVA) model that included fixed 
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categorical effects of titration regimen group and stratum of randomization of 
previous use of insulin (insulin-naïve vs non-insulin-naïve) as well as the continuous 
fixed covariate of baseline HbA1c value. The change in FPG from baseline to Week 16 
was analyzed using a similar MMRM model as performed for the change in mean 
FSMPG. The adjusted LS means estimates at week 16 for both titration groups, as 
well as the differences of these estimates, with their corresponding SEs and 95% CIs 
were provided. The pre-specified FPG target was analyzed using Cochran Mantel 
Haenszel (CMH) method with titration group as factor and stratified on the 
randomization stratum of previous use of insulin, providing relative risk estimates 
and corresponding 95% confidence intervals. 
 
Safety analyses were descriptive and based on the safety population. For 
participants in the device-supported arm, AEs were reported for the on-treatment 
period and device-supported period (device-emergent). Any suspected problem with 
the device such as meter performance failure, participant (or caregiver) having 
difficulty understanding the instructions or user error, which led or may have led to 
a AEs was reported as a meter-related event (MRE). 
 
Patient-reported outcomes (PRO)/questionnaire ANCOVA model: included fixed 
categorical effects of titration group, randomization stratum of previous use of 
insulin (insulin-naïve, non-insulin-naïve), as well as the continuous fixed covariate of 
baseline PRO value. Percentage of PROs responders, defined by the number of 
patients with a change from baseline of PRO total scores equal or superior (for 
diabetes treatment satisfaction questionnaire [DTSQ], glucose monitoring 
satisfaction survey [GMS] and WHO-5 well-being index) or equal or less (for 
hypoglycemia fear survey [HFS-II] and diabetes distress scale) to the minimum 
clinically important difference (MCID), was analyzed using a CMH method. For each 
PRO score, the MCID value was defined as the half of the standard deviation of the 
PRO score at baseline within the whole mITT population. 
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Supplementary Table 1. Dosing recommendations for device-supported titration 
FSMPG 
Gla-300 dose (U/day) 
adjustment 
>180 mg/dL (>10.0 mmol/L)  +4Ua 
>130 mg/dL (>7.2 mmol/L) +2U 
90-130 mg/dL (5.0 to 7.2 mmol/L) or within target 
range 
No change 
<90 mg/dL (5.0 mmol/L) and >70 mg/dL (3.9 mmol/L) −2U 
<70 mg/dL (<3.9 mmol/L) −4U 
aDose increase every 3 days if FSMPG above target. Gla-300, insulin glargine  
300 U/mL; FSMPG, fasting self-monitored plasma glucose 
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Supplementary Table 2. Overview of treatment-emergent adverse events (safety population) 
 
Type of TEAE, n (%) 
Device-supported titration 
(n=75) 
Routine titration 
(n=76) 
On-treatment 
period 
Device-support 
period 
On-treatment 
period 
Any 34 (45.3) 32 (42.7) 29 (38.2) 
Serious  2 (2.7) 2 (2.7) 3 (3.9) 
TEAE leading to treatment discontinuation 0 0 0 
TEAE leading to death 0 0 0 
Meter-related eventa 53 (70.7) 52 (69.3) 7 (9.2) 
Pen-related event 3 (4.0) 3 (4.0) 3 (3.9) 
PTC for the meter 15 (20.0) 15 (20.0)  0  
PTC for the pen 1 (1.3) 1 (1.3) 1 (1.3) 
n (%) = number and percentage of participants with at least one TEAE.  
aAny suspected problem with the device such as meter performance failure, participant (or caregiver) having difficulty understanding the instructions or user error, which led or may have led 
to a AEs was reported as a meter-related event. 
PTC, product technical complaint; TEAE, treatment-emergent adverse event
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Supplementary Table 3. Patient reported outcomes during the 16 week on-
treatment period (modified intent-to-treat population) 
Change from baseline to week 16, LS 
mean (SE) 
Device-supported 
titration 
(n=75) 
Routine titration 
(n=76) 
Total treatment satisfaction score 2.90 (0.612) 4.46 (0.596) 
Total HFS-II score 0.00 (0.050) 0.03 (0.048) 
Total Diabetes Distress Scale score 0.08 (0.060) -0.04 (0.058) 
Total GMS score 0.10 (0.071) 0.30 (0.069) 
WHO-5 well-being index score −0.03 (1.788) 6.20 (1.750) 
The Diabetes Treatment Satisfaction Questionnaire (DTSQs) consists of 8 items scored on a 7-point 
scale with a higher score indicating greater satisfaction. HFS-II consists of 33 items in 2 subscales HFS-B 
(behavior to avoid hypoglycemia) and HFS-W (worry about hypoglycemia). It is rated on a 5-point Likert 
scale ranging from 0 (never) to 4 (always). The Diabetes Distress Scale consists of 17 items scored on a 
7-point scale rated from 1 (not a problem) to 6 (a very serious problem). The GMS consists of 15 items 
scored on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). The WHO-5 well-
being index includes five items rated on a 6-point scale with 0 (at no time) to 5 (all the time). The total 
raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst 
imaginable well-being and 100 representing the best imaginable well-being. GMS, glucose monitoring 
satisfaction survey; HFS-II, hypoglycemia fear scale; LS, least squares; SE, standard error; WHO, World 
Health Organization. 
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Supplementary Table 4. Improvements that have been made to the dose-helper 
device (MyStar DoseCoach™, Agamatrix Inc., Salem NH, US) following the 
AUTOMATIX study 
 
Issue identified Solution 
• Users not understanding 
tagging and the importance of 
applying a fasting tag 
• New screens added to improve 
accuracy of tagging: 
o "Is this a fasting 
reading?" if blood 
glucose test 
performed within the 
usual fasting window 
o New "fasting readings 
are used by dose-
helper to determine 
dose suggestions" has 
been added 
o The "fasting tag" 
selection has been 
greyed out when 
outside usual fasting 
time 
• Users getting stuck in the 
dose-helper function not being 
able to get out 
• Exit path provided from the 
dose-helper flow. Added "exit" 
button to "back button 
unavailable" screen and the 
wording has been clarified 
• Previous dose prompt found to 
be confusing when the dose-
helper is used for the first time 
• New screen has been added to 
show if dose-helper is being 
run for the first time 
• Users pressing the dose-helper 
button when they wanted to 
change the dose time. 
• New "Welcome to dose-
helper" menu screen and 
dose-helper settings screens 
have been added. The dose-
helper icon has also been 
changed to a wrench for 
settings selection. 
• Users misunderstanding the 
previous dose question 
• The "previous dose question" 
and "additional dose question" 
screen has been broken into 
two screens so that the day 
picker is one screen and the 
time picker is on second 
screen. Time picker has been 
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restricted to valid choices 
• Twice-daily screen prompt was 
confusing for some users 
• The wording on two screens 
has been changed to clarify if 
twice daily dosing has been 
prescribed 
• Hypoglycemia questions were 
found to be confusing 
• The possible number of 
answers to the hypoglycemia 
questions have been reduced 
from six to three; three 
screens have been reworded 
and one screen split into two 
for clarification 
• Use of the left soft key for 
back navigation was found to 
be confusing 
• Added six new screens at 
initial start-up to explain 
navigation (how buttons work) 
• Improved feedback for the 
chosen time values required 
• The sequence of time/date 
screens has been changed by 
moving the last three screens 
to be the first three screens. 
New screen has been added to 
confirm the time/date, and 
text added to time screens 
• Users not understanding that 
they need to scroll down to 
read the full “User Agreement 
Screen” 
• Wording and button icon has 
been added to two screens 
• Improved differentiation of 
the activation key artwork 
required for healthcare 
providers 
• One new screen has been 
added to inform healthcare 
providers that each key 
unlocks a different treatment 
plan 
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Supplementary Figure 1. Study Design 
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Supplementary Figure 2. Study participant disposition (randomized population) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
aA patient was considered to have completed the study period if they attended the week 16 visit, 
irrespective of treatment and device compliance. 
 
Discontinued treatment with Gla-300 
prematurely n=5 
Reasons: 
Withdrawal of consent, n=3  
Poor compliance to protocol, n= 1 
Inability to use the device, n=1  
Did not complete the device-
supported period n=17 
Reasons: 
Misunderstanding of the device 
function use, n=9  
Other reason, n= 8 
 
Enrolled 
N=151 
Device-supported titration 
n=75 
Routine titration 
(investigator-recommended) 
n=76 
Completed the 
studya 
n=70 
Completed the 
studya 
n=76 
